RxDoctor Payments Data

Miguel Parilo, MD

Internal Medicine · Dayton, OHNPI 1255386744

Payments from drug & device makers

$84,423in general payments, 2019–2025

Across 104 payments — averaging $811.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$84K
  • Sanofi$162
  • Lilly USA, LLC$12

What the payments were for

  • Speaking & faculty fees$82,43498%
  • Travel & lodging$7301%
  • Food & beverage$1,2481%
  • Education$120%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC101$84,250
Sanofi2$162
Lilly USA, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,423 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$174,488
Medicare patients
562
Services billed
3,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide608$795,706
MounjaroTirzepatide370$507,414
TrulicityDulaglutide386$501,526
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog351$364,623
JardianceEmpagliflozin339$361,680
FarxigaDapagliflozin Propanediol384$358,256
Soliqua 100-33Insulin Glargine/Lixisenatide172$186,363
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/773$130,509
Humalog Kwikpen U-200Insulin Lispro55$102,525
Synjardy XrEmpagliflozin/Metformin Hcl78$101,588
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog147$75,091
Humalog Kwikpen U-100Insulin Lispro197$64,293
Xigduo XrDapaglifloz Propaned/Metformin74$62,988
Tresiba Flextouch U-200Insulin Degludec47$62,946
JanuviaSitagliptin Phosphate43$47,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev, Insulin Lispro$12$1,077,551976 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Admelog$84,250$199,529192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →